Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNavy General Hospital, Beijing
About this trial
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE.
Eligibility criteria
Qualifiers
Inpatients ≥18 years of age at admission;
At high-risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients;
Signed informed consent.
Disqualifiers
Diagnosis of VTE at discharge;
Mental disorder or combination of other serious diseases leading to incapacity for independent living;
Inability to use smartphones, computer tablets and other smart devices;
Being pregnant or breastfeeding;
Trial design
Treatments tested in this trial
- mobile venous thromboembolism application (mVTEA)
Treatment groups
2,353 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov